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Pseudomonas aeruginosa is a multi-drug resistant pathogen, fertile within the hospital 
setting. Known to be causal of many respiratory infections, the treatment of this gram negative 
microorganism is complicated by an intrinsic and acquired resistance profile. An example of 
intrinsic resistance would be an impermeable outer membrane common to many gram negative 
bacteria.  
 A separate method of intrinsic and acquired resistance comes through the activity of 
efflux pumps within mutant strains of P. aeruginosa and other gram negative bacteria7-10. 
Presently, there are four efflux pump systems that have been extensively studied: MexAB-OprM, 
MexCD-OprJ, MexEF-OprN, and MexXY-OprM. These efflux pumps operate by capturing 
antimicrobial compounds within the periplasm, cytoplasmic space, or plasmalemma and ejecting 
them outward into the extracellular matrix through a three protein conduit. Efflux pumps are 
energy dependent using a proton motive driving force.7 Although these efflux pumps have broad 
substrate ranges, the greatest is seen with MexAB-OprM; not all compounds are susceptible to 
the activity of each pump. An example would be aztreonam that shows inefficacy as an 
antimicrobial for the treatment of P. aeruginosa when the particular strain overproduces MexAB-
OprM. However with the overproduction of other Mex-Opr efflux pumps, the aztreonam 
Minimum Inhibitory Concentration (MIC) may remain at approximate values.  
 The MexAB-OprM efflux pump is produced by the mexA-mexB-oprM operon gene7-8. 
This pump is produced at low levels constitutively in all strains of P. aeruginosa. This implies 
that this efflux pump system is a contributor to both the intrinsic and acquired resistance profile. 
Overproduction occurs within nalB mutants, increasing resistance to aztreonam, the β-lactams, 
β-lactamase inhibitors, cephalosporins, quinolones, the penems, and tetracyclines7-8.  
 MexCD-OprJ and MexEF-OprN are overproduced by nfxB and nfxC mutants, 
respectively. Substrates for the MexCD-OprJ efflux pump include cefepime, chloramphenicol, 
the quinolones, erythromycin, and tetracycline. MexEF-OprN substrates are largely similar: 
chloramphenicol, the quinolones, imipenem, and trimethoprim7-8. The fluoroquinolones tend to 
select for MexCD-OprJ or MexEF-OprN among other efflux types. Sub-inhibitory 
concentrations of the quinolones have been shown to induce increased MexCD-OprJ 
production.8 However, the documentation of Efflux Pump Overexpression (EPO) with the 
fluoroquinolones is difficult because the MIC may not increase above the National Committee 
for Clinical Laboratory Standards (NCCLS) established levels7. 
 Selective substrates for MexXY-OprM are the aminoglycosides9. Other substrates include 
amikacin, cefepime, cefotaxime, erythromycin, tetracycline, and the quinolones. MexXY-OprM 
over-expression can occur due to sub-inhibitory concentrations of respective substrates similar to 
the fluoroquinolones and MexCD-OprJ.6 
 Other potential causes for EPO include a greater bacterial inoculum, decreased 
environmental pH because of the proton motive driving force allowing efflux pump activity, and 
intercellular signaling7. Communication allows genetic activation of efflux pump expression. In 
P. aeruginosa, the Mex-Opr pumps regulate at least one homoserine lactone signaling molecule 
involved in this process7, 11. 
 Previous studies have attempted to determine any causal factors that can promote the 
development of resistance. A six year study identified age greater than 65 years, prior exposure 




significant risk factors for the harboring of multi-drug resistant gram negative organisms. 6 Other 
factors identified tend to rely heavily on the previous or prolonged use of certain antibiotics, in 
particular imipenem or the fluoroquinolones1.  Both antibiotics tend to select for resistant forms 
of P. aeruginosa, in particular the presence of efflux pumps with the use of fluoroquinolones. 
Cancer patients, for example, showed a significant increase in multi-drug resistance (MDR) of P. 
aeruginosa strains if exposed to carbapenem for greater than seven days or if there was a history 
of chronic obstructive pulmonary disease (COPD).2  
 One study was that by B. Cao, et al.3 This was a 44 month retrospective cohort study. 
Results showed, through multivariate analysis, that previous exposure to imipenem or 
meropenem within the previous fifteen days of isolation and previous mechanical ventilation 
greater than 48 hours were risk factors for MDR P. aeruginosa; this has similarly been 
documented with cystic fibrosis patients. While in the respiratory tract P. aeruginosa has the 
ability to form biofilms that serve as a form of protection and promote additional resistance. 
Univariate analysis cited MDR strains were largely greater in elderly, ICU, COPD / 
bronchiectasis, and higher APACHE II scoring patients. This also included patients with 
polymicrobial infections and those that received fluoroquinolones or imipenem / meropenem 
within the previous fifteen days before strain isolation. Of further interest is that of all the 
antibiotics, imipenem had the highest ratio for the emergence of antibiotic resistance in P. 
aeruginosa. This response also induced resistance to other agents including the fluoroquinolones, 
cephalosporins, and anti-pseudomonal penicillins.3 
Considering imipenem resistance, a three year case control study by Harris et al. 
compared patients that either had imipenem resistant or susceptible P. aeruginosa strains.4 The 
purpose of this study was to find risk factors for the development of imipenem resistance.    
Bivariate and multivariate analysis showed that imipenem resistant strains were 
significantly greater in the diabetic population and in those patients with an increased length of 
stay, ICU transfer, or previous admission. Patients were also significantly more apt to have 
imipenem resistant P. aeruginosa if previously treated with imipenem, piperacillin-tazobactam, 
vancomycin, first or third generation cephalosporins, aminoglycosides, or quinolones.4  
As shown, even though imipenem is largely known to be a consistently repeating cause 
of MDR, other antibiotics and even comorbidities may also be responsible or influential. This 
even includes antibiotics that have no anti-pseudomonal activity, such as the glycopeptides.  
Certain disease states tend to be associated more with resistance which includes 
circulatory, cardiovascular, and genitourinary disorders. The fact that diseases of the 
genitourinary system prefer the development of resistant isolates is not surprising. This is 
because most patients with urinary tract infections are treated with trimethoprim, 
fluoroquinolones, or the β-lactams. Considering the fluoroquinolones that are hepatically 
metabolized, subtherapeutic concentrations most likely accumulate within the urinary tract 
promoting resistance. This is especially applicable to EPO, since again sub – therapeutic 
concentrations of fluoroquinolones have been shown to induce the expression of MexCD-OprJ. 
Furthermore, considering that older patients tend to have renal diseases and insufficiencies, this 
can provide additional reasons for the easy accumulation of bacterium within this setting. 
Considering chronic alcoholism, one hypothesis is that the lack of proper dietary habits 
and malnutrition upset the balance of normal gastrointestinal flora. Thereafter a virulent 
bacterium, such as P. aeruginosa may thrive, evolve into a resistant organism, and translocate. 




would agree with the results of the Harris et al. study that found a greater amount of MDR P. 
aeruginosa isolates in the diabetic population.4 
 One study by C. Defez et al. studied patients if they presented with a MDR P. aeruginosa 
nosocomial infection for the first time. Univariate analysis showed MDR to be significantly 
greater in older patients. Bivariate analysis stated that MDR was greater in patients that were 
exposed to previous antimicrobial medications, in particular the β-lactams, macrolides, 
glycopeptides, fluoroquinolones, and imidazoles. This was further analyzed using multivariate 
analysis that showed previous exposure to β-lactams or fluoroquinolones were significantly 
associated with MDR P. aeruginosa.5  
In relation to chronic alcoholism and diabetes though this study also noted that urinary 
catheterization was also associated with MDR within these patient subtypes. An additional 
interesting discovery was that patients fed through a nasogastric tube were also more likely to 
have MDR. This was possibly due to the weakening of the digestive mucosa causing easier 
translocation of P. aeruginosa post an imbalance of the normal gut flora.5 This could have 
possible application to chronic alcoholism or diabetes, making these comorbidities possible risk 
factors. 
 Although much research has investigated the genetics of Mex-Opr efflux pumps, 
knowledge of the clinical prevalence and significance of EPO is novel. These topics tend to not 
be included with most epidemiologic studies. Further complications include the lack of literature 
addressing differences in duration of treatment, outcome, and therapy prescribed between EPO 
positive and negative strains. In the clinical setting current guidelines for susceptibility testing is 
to label an antibiotic as either susceptible or resistant based on MIC breakpoints established by 
the NCCLS. However the data presented does not routinely show progressive changes in the 
MIC over the duration of antibiotic treatment. EPO is both an innate and acquired resistance 
mechanism that does not necessarily increase the MIC above the breakpoint levels but can still 
significantly impact clinical progress of a patient and eventually be a cause of treatment failure. 
Considering EPO and other resistance mechanisms it is important to design appropriate therapy 
based not only if a strain is susceptible or resistant but also upon the strain’s degree of 
susceptibility. This knowledge can help to ensure microbiological and clinical treatment success, 
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